Histology

Medical Journal: Image-Guided Superficial Radiation Therapy Is Superior to Superficial Radiation Therapy Without Guidance

Retrieved on: 
Tuesday, February 20, 2024
Mohs surgery, Skin cancer, Freedom, Recurrence, Carcinoma, Toxicity, SRT, American Academy of Dermatology, Research, ASTRO, FDA, Skin, BCC, Radiation, SCC, NMSC, Society, Silverman, Patient, Histology, Photon, Radiation therapy, Cancer, American Academy, Medical imaging

BURR RIDGE, Ill., Feb. 20, 2024 /PRNewswire/ -- SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT or IGSRT) for the treatment of nonmelanoma skin cancer, presented to dermatology patients as the GentleCure™ experience, announced the publication of research, "Image guidance improves freedom from recurrence in superficial radiation therapy for non-melanoma skin cancer," in Advances in Radiation Oncology, a peer-reviewed journal from the American Society for Radiation Oncology (ASTRO).

Key Points: 
  • It shows definitively that the new technology is superior, and represents a seminal moment in the care of skin cancer patients using radiation.
  • This study is the first to rigorously compare SRT to IGSRT, and it covers all the data that exists on IGSRT.
  • Superficial radiation therapy was developed over 100 years ago ( here ) and was the standard therapy for nonmelanoma skin cancer until Mohs micrographic surgery emerged in the 1930's ( here ).
  • IGSRT and the GentleCure experience will be showcased at the upcoming American Academy of Dermatology annual meeting in San Diego, at booth 3555.

Anika Highlights Its Recently Launched Integrity™ Implant System and RevoMotion™ Reverse Shoulder Arthroplasty System Along with Other Key Regenerative Products During the 2024 AAOS Annual Meeting

Retrieved on: 
Tuesday, February 13, 2024
Motion, MD, PET, Materialise NV, Anika, Next Generation, Partnership, Physician, Surgeon, Shoulder, AIM, RSA, Annual general meeting, Elective surgery, Therapy, Hyaluronic acid, TSA, Patient, Histology, AAOS, Sports medicine, Integrity, Medicine, American Academy, Dentistry

BEDFORD, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company, today announced it is highlighting recently-launched products in high growth segments of joint preservation and restoration from its Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions businesses during the 2024 American Academy of Orthopedic Surgeons (AAOS) Annual Meeting on February 13-15 in San Francisco, CA. Throughout the event, Anika will feature its differentiated shoulder portfolio including the recently launched Integrity Implant System for rotator cuff repair, RevoMotion Reverse Shoulder Arthroplasty (RSA) System with newly launched AIMTM (Anika Implant Management) surgical planning software, X-Twist Fixation System with biocomposite suture anchor, OVOMotion® with Inlay Glenoid Total Shoulder Arthroplasty (TSA) System, and many more of its early intervention orthopedic solutions, in booth #5145.

Key Points: 
  • “Anika is excited to highlight our recently launched Integrity Implant System, our newest regenerative hyaluronic acid (HA)-based scaffold for rotator cuff repair, and our X-Twist Fixation System with biocomposite suture anchor.
  • We have also enhanced our shoulder arthroplasty offerings with the launch of AIM, Anika Implant Management, for 3-D preoperative planning which is now available with both the RevoMotion Reverse Shoulder and OVOMotion Total Shoulder arthroplasty systems.
  • The RevoMotion Reverse Shoulder Arthroplasty System, with the industry’s smallest diameter threaded baseplate, offers surgeons and patients the ability to restore motion and preserve bone.
  • Several new Sports Medicine products will also be available in early 2024, including the ProPass™ Suture Passer, and other new shoulder instrumentation.

David Bruning Named Chief Executive Officer of StageBio

Retrieved on: 
Monday, February 12, 2024
Pathology, Growth, Life Technologies, Histology, Sigma-Aldrich

JACKSON, Va., Feb. 12, 2024 /PRNewswire/ -- StageBio, a leading provider of GLP-compliant histology, pathology, image analysis and archiving services for both preclinical and clinical research, is pleased to announce the appointment of David Bruning as Chief Executive Officer.

Key Points: 
  • JACKSON, Va., Feb. 12, 2024 /PRNewswire/ -- StageBio, a leading provider of GLP-compliant histology, pathology, image analysis and archiving services for both preclinical and clinical research, is pleased to announce the appointment of David Bruning as Chief Executive Officer.
  • Having served on the StageBio Board of Directors for the past five years in addition to previously being a longstanding customer of StageBio, Mr. Bruning possesses a deep understanding of the company, its strategic priorities and the evolving needs of its customers.
  • On his appointment as CEO, Mr. Bruning comments, "I'm grateful for the opportunity to lead StageBio in its next phase of growth.
  • David's understanding of the business and its customers, coupled with his industry expertise, positions him for success in driving continuous growth for StageBio in 2024 and beyond."

StatLab Medical Products Announces New Facility Opening

Retrieved on: 
Monday, February 12, 2024
Other Manufacturing, Research, Medical Devices, Medical Supplies, Hospitals, Chemicals, Plastics, Manufacturing, Health, Science, Acquisition, Multimedia, Partnership, Carbon, Ecosystem, Histology, Laboratory, Workflow

StatLab Medical Products (StatLab), a leading global developer and manufacturer of medical diagnostic equipment and supplies, announces the commencement of injection molding manufacturing at a new, state-of the-art histology consumable manufacturing facility in Arlington, Texas.

Key Points: 
  • StatLab Medical Products (StatLab), a leading global developer and manufacturer of medical diagnostic equipment and supplies, announces the commencement of injection molding manufacturing at a new, state-of the-art histology consumable manufacturing facility in Arlington, Texas.
  • This represents a new era of innovation and transformational opportunity for StatLab with a new essential manufacturing capability for histology solutions now actively operating in the United States.
  • View the full release here: https://www.businesswire.com/news/home/20240212393712/en/
    The new StatLab histology consumable manufacturing facility, where injection molding is operational, producing histology cassettes—a critical component of the histology workflow in laboratories.
  • A short reception and facility tours will follow through 2PM.

Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)

Retrieved on: 
Thursday, January 25, 2024
Ageing, Regeneron Pharmaceuticals, Patient, Histology, Failure, Diagnosis, Medicine, Heartburn, Risk, Lower respiratory tract infection, Food, Arthralgia, Chronic pain, Safety, Disease, Esophagus, Inflammation, Helminthiasis, Priority review, FDA, Eosinophilic esophagitis, Prevalence, Vomiting, International development, Growth, Pharmaceutical industry

TARRYTOWN, N.Y. and PARIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic esophagitis (EoE). Dupixent is now the first and only medicine approved in the U.S. specifically indicated to treat these patients. This approval expands the initial FDA approval for EoE in May 2022 for patients aged 12 years and older, weighing at least 40 kg. The FDA evaluated Dupixent for this expanded indication under Priority Review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in treating serious conditions.

Key Points: 
  • Dupixent is now the first and only medicine approved in the U.S. specifically indicated to treat these patients.
  • This approval expands the initial FDA approval for EoE in May 2022 for patients aged 12 years and older, weighing at least 40 kg.
  • Approximately 21,000 children under the age of 12 in the U.S. are currently being treated for EoE with unapproved therapies.
  • “With this approval, Dupixent becomes the first and only treatment option for EoE patients aged 1 and older, weighing at least 15 kg.

Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)

Retrieved on: 
Thursday, January 25, 2024
Ageing, Patient, Histology, Failure, Diagnosis, Medicine, Heartburn, Risk, Lower respiratory tract infection, Food, Arthralgia, Chronic pain, Safety, Disease, Esophagus, Helminthiasis, FDA, Priority review, Inflammation, Eosinophilic esophagitis, Vomiting, Prevalence, Growth, Pharmaceutical industry

The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic esophagitis (EoE).

Key Points: 
  • The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic esophagitis (EoE).
  • Dupixent is now the first and only medicine approved in the U.S. specifically indicated to treat these patients.
  • This approval expands the initial FDA approval for EoE in May 2022 for patients aged 12 years and older, weighing at least 40 kg.
  • With this approval, Dupixent becomes the first and only treatment option for EoE patients aged 1 year and older, weighing at least 15 kg.

Gilead Provides Update on Phase 3 EVOKE-01 Study

Retrieved on: 
Monday, January 22, 2024
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Patient, Research, MD, Histology, ADC, Science, Survival, Docetaxel, Lung cancer, Immunotherapy, NSCLC, Gilead Sciences, Conference, Safety, Diarrhea, Doctor of Philosophy, Pembrolizumab, Lung, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC).

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC).
  • A numerical improvement in OS favoring SG was observed in the study, including in patients with both squamous and non-squamous histology.
  • Based on strong preliminary efficacy and safety data from the Phase 2 EVOKE-02 study of Trodelvy in combination with pembrolizumab, presented at the World Conference on Lung Cancer 2023, Gilead remains confident in its ongoing Phase 3 EVOKE-03 study in 1L metastatic PD-L1 high NSCLC.
  • In addition, Gilead has a broad clinical development program in lung cancer with domvanalimab, the first Fc-silent investigational anti-TIGIT antibody.

AtlasXomics and EpiCypher announce partnership to commercialize spatial epigenomics assays

Retrieved on: 
Tuesday, January 23, 2024
Epigenomics, Chromatin, Research, Traction, Histology, Partnership, Science, Determinism, Tissue, Molecular biology, Business, CUT, Spatial, Factorization of polynomials, Business development, Howard Hughes Medical Institute, Yale University, Disease, Biomedical engineering, Laboratory, Antibody, Biomedicine, Protein, ATAC, Microfluidics, Medicine

NEW HAVEN, Conn. and RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2024 /PRNewswire/ -- AtlasXomics and EpiCypher announce their partnership to develop CUT&Tag kits and assay services for spatial epigenomics applications.

Key Points: 
  • NEW HAVEN, Conn. and RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2024 /PRNewswire/ -- AtlasXomics and EpiCypher announce their partnership to develop CUT&Tag kits and assay services for spatial epigenomics applications.
  • The application of ultra-sensitive chromatin mapping assays, such as CUT&Tag, to spatial techniques is critical to the study of biological mechanisms in development and disease.
  • AtlasXomics has commercialized DBiT-seq for spatial ATAC-seq assays to map chromatin accessibility and is partnering with EpiCypher to introduce spatial CUT&Tag for profiling chromatin proteins, including histone PTMs and transcription factors.
  • EpiCypher holds key rights to CUT&Tag technology and a proprietary nucleosome-based approach to develop ultra-efficient antibodies for spatial and single cell CUT&Tag assays.

NanoString’s CosMx SMI Achieves Whole Transcriptome Imaging at Single-Cell Resolution

Retrieved on: 
Sunday, January 7, 2024
Health, Diabetes, Genetics, Other Science, Research, Science, Biotechnology, RNA, Conference, Transcriptome, Software, Histology, Anatomy, Colorectal cancer, Data, Pancreas, SMI, Brain, PLEX, Pancreatic cancer, Gene, Genome, Cell, Physiology

NanoString is the first company to achieve the scientific breakthrough of providing true single-cell whole transcriptome imaging.

Key Points: 
  • NanoString is the first company to achieve the scientific breakthrough of providing true single-cell whole transcriptome imaging.
  • The CosMx Whole Transcriptome Panel transforms the potential to extract biological insights from formalin-fixed paraffin-embedded (FFPE) tissue samples.
  • NanoString is marking this milestone achievement with the public release of a whole transcriptome CosMx SMI dataset generated from FFPE samples of healthy human pancreas tissue.
  • Customers who have gained access to prototypes of the CosMx Whole Transcriptome Panel will present datasets generated on pancreatic cancer, colorectal cancer, and human brain.

Global In Vitro Diagnostic (IVD) Procedure Volumes Report 2023-2028: The Gold Standard for Sizing Chemistry, Immunoassays, Hematology, Microbiology, Histology, Point of Care Market Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, January 5, 2024
Health, Other Health, Research, Chemistry, Microbiology, Histology, IVD

The "In Vitro Diagnostic (IVD) Procedure Volumes (Chemistry, Immunoassays, Hematology, Microbiology, Histology, Point of Care), 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "In Vitro Diagnostic (IVD) Procedure Volumes (Chemistry, Immunoassays, Hematology, Microbiology, Histology, Point of Care), 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • In vitro diagnostic (IVD) test volumes are the gold standard for sizing the market opportunity for new entrants with diagnostic products, and they can be useful for existing product marketers.
  • The market analysis in the report saves time with calculations and estimates of both the existing number of procedures for scores of diagnostic tests and the future potential.
  • Data statistics appearing in this report correlate to IVD procedures based on commercially sold and distributed tests.